Combination therapies

Patent metadata

Field	Value
Publication number	US-12377101-B2
Application number	US-201917275181-A
Country	US
Kind code	B2
Filing date	Dec 5, 2019
Priority date	Dec 5, 2018
Publication date	Aug 5, 2025
Grant date	Aug 5, 2025

Abstract

The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SHP-2 inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

First claim

What is claimed is:

1. A method of treating KRAS G12C-associated cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SHP-2 inhibitor and a KRAS G12C inhibitor, wherein said KRas G12C inhibitor is:

or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 , wherein the SHP-2 inhibitor is SHP-099 (6-(4-Amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl) pyrazin-2-amine dihydrochloride); RMC-4550 (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro [4.5]decan-8-yl)-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl) methanol), RMC-4360 or TNO155 .

3. The method of claim 2 , wherein the SHP-2 inhibitor is SHP-099.

4. The method of claim 2 , wherein the SHP-2 inhibitor is RMC-4550.

5. The method of claim 2 , wherein the SHP-2 inhibitor is RMC-4360 or TNO155.

6. The method according to claim 1 , wherein the therapeutically effective amount of the combination of the SHP-2 inhibitor and the KRAS G12C inhibitor results in an increased duration of overall survival, an increased duration of progression free survival, an increase in tumor growth regression, an increase in tumor growth inhibition or an increased duration of stable disease in the subjects relative to treatment with only the KRAS G12C inhibitor.

7. A method for inhibiting KRAS G12C activity in a cancer cell, comprising contacting the cancer cell in which inhibition of KRAS G12C activity is desired with an effective amount of a SHP-2 inhibitor and a KRAS G12C inhibitor compound having the formula:

pharmaceutical compositions or pharmaceutically acceptable salts thereof, wherein the SHP-2 inhibitor synergistically increases the sensitivity of the cancer cells to the KRAS G12C inhibitor.

8. The method according to claim 1 , wherein the SHP-2 inhibitor synergistically increases the sensitivity of the cancer to the KRAS G12C inhibitor.

9. A method for increasing the sensitivity of a cancer cell to a KRAS G12C inhibitor compound comprising administering to a subject undergoing KRAS G12C treatment with a compound having the formula:

or a pharmaceutically acceptable salt thereof, alone or combined with a pharmaceutically acceptable carrier, excipient or diluents, a therapeutically effective amount of a SHP-2 inhibitor, wherein the SHP-2 inhibitor synergistically increases the sensitivity of the cancer cell to the KRAS G12C inhibitor.

10. The method according to claim 1 , wherein the therapeutically effective amount of the KRAS G12C inhibitor in the combination is between about 0.01 to 100 mg/kg per day.

11. The method of claim 1 , wherein the cancer is non-small cell lung cancer.

Assignees

• Mirati Therapeutics Inc

Inventors

• Christensen James Gail
• Engstrom Lars Daniel
• Olson Peter
• Aranda Ruth Wei

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/497

  containing further heterocyclic rings · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title